Laformin-G 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The combination of these agents provides complementary mechanisms to achieve better glycemic control in patients inadequately managed by diet and exercise alone. Laformin-G 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring. It is important to administer the medication with meals to reduce gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose and periodic assessment of renal function are recommended during therapy. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and rare instances of lactic acidosis. Patient education on recognizing hypoglycemia symptoms and adherence to prescribed dosage is essential for optimal therapeutic outcomes.